Redpoint Bio to Present at the 10^th Annual BIO CEO & Investor Conference

EWING, N.J.--(BUSINESS WIRE)--Redpoint Bio Corporation (OTCBB: RPBC), a company developing ingredients to improve the taste of pharmaceutical, food and beverage products, today announced that Chief Executive Officer, Dr. Ray Salemme, will present an overview of the Company at the 10^th Annual BIO CEO & Investor Conference in New York on Wednesday, February 13, 2008 at 2:00pm Eastern Time in the Basildon Room at The Waldorf Astoria Hotel.

Interested parties may access the webcast at http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=RPBC&item_id= 1752445, or on the Company’s website at http://www.redpointbio.com. (Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.)

About Redpoint Bio Corporation

Redpoint Bio is leveraging recent discoveries in the molecular biology of taste to discover and develop novel taste modulators for the food, beverage and pharmaceutical industries. Redpoint Bio's food and beverage program is focused on identifying novel flavors that improve the tastes of existing ingredients and enable the development of better-tasting foods and beverages. The pharmaceutical program uses a biochemical approach aimed at suppressing the bitterness of medicines, which has the potential to expand the range of formulation options and increase patient compliance. For more information, please visit the Company's website at www.redpointbio.com.

Safe Harbor Statement

In addition to historical facts or statements of current condition, this press release contains forward-looking statements within the meaning of the "Safe Harbor" provisions of The Private Securities Litigation Reform Act of 1995. Forward-looking statements provide the Company's current expectations or forecasts of future events. The Company's performance and financial results could differ materially from those reflected in these forward-looking statements due to among other factors, uncertainty inherent in the discovery phase of technological development, any efforts by third parties to invalidate or limit any patents, the marketplace acceptance of its products, the decisions of regulatory authorities, the results of clinical trials and general financial, economic, regulatory and political conditions affecting the food, biotechnology and pharmaceutical industries generally. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. The Company undertakes no obligation to update publicly any forward-looking statement.